The Drug Discovery World Podcast DDW Highlights: 13 January 2025
Jan 13, 2025
Explore the latest developments in drug discovery, including a pharmaceutical company's strategic acquisition aimed at CNS treatments. Learn about innovative partnerships, like those between Vertex Pharmaceuticals and Orna Therapeutics, driving advancements in gene therapies. Discover a promising collaboration focused on ALS therapies, as well as Xylo Core Therapeutics' impressive funding success to further angina treatment research. The podcast covers exciting industry trends and insights as 2025 kicks off with strong momentum.
AI Snips
Chapters
Transcript
Episode notes
Nuraxfarm expands CNS portfolio
- Nuraxfarm acquired Provigil and Nuvigil to treat excessive daytime sleepiness.
- This acquisition expands their CNS portfolio and reach in Europe, Australia, and Mexico.
Vertex and Orna partner on gene therapies
- Vertex Pharmaceuticals and Orna Therapeutics partnered on gene therapies for sickle cell disease and beta-thalassemia.
- Orna will use its lipid nanoparticle delivery solutions and receive upfront payments and potential milestones.
Aspect Biosystems raises $115 million
- Aspect Biosystems secured $115 million in Series B funding to advance bioprinted tissue therapeutics.
- The funding will support clinical trials for cellular medicines targeting metabolic and endocrine diseases.